Tirzepatide is now approved for obstructive sleep apnea with obesity, and this desk has treated that as a purchasing question in treating it and preventing it are different purchases. This survey asks a different one: what clinics actually do when someone on a CPAP machine starts losing substantial weight [1]. The survey covered 24 centers across 14 countries (n = 24), so every percentage below is a share of centers rather than of patients.
Most of the answers are sensible. Ninety-two percent of centers still recommend a diagnostic sleep study in symptomatic patients recently started on one of these drugs, and 81% do so even when patients are asymptomatic — sensible, because improvement on a scale is not evidence of improvement in breathing. Sixty-one percent treat weight loss above 10% as the threshold for reassessment.
There is a reason for the caution, and it is a good one. Untreated sleep apnea is dangerous, withdrawing pressure therapy requires evidence that it is no longer needed, and that evidence comes from a sleep study rather than from a number on a scale. Nothing here is an argument for adjusting your own machine, and anyone reading it that way would be taking a real risk for no benefit.
What it is an argument for is asking. If you are on pressure therapy and have lost substantial weight on one of these drugs, a reassessment is something to request rather than wait for — most centers will not initiate it, and the equipment, the supplies and the follow-up all carry ongoing cost, set against the drug in what sleep apnea costs. The size of improvement to expect, and why it varies so much by how severe the apnea was to begin with, is examined on this site’s sister publication.
Two limits on reading this across. It surveys specialist European sleep centers, which are not the US telehealth sellers most readers of this desk buy from, and the percentages are of centers rather than patients — 42% means ten centers out of twenty-four. What it establishes is that even in well-resourced specialist practice the handoff between weight treatment and sleep treatment is improvised, which is consistent with the variability patients report in what patients said when asked and with the support gap in every drug worked better with support attached.